Boston Scientific said it will pay $374 a share in cash and stock for Penumbra, which makes products to remove blood clots ...
A new report finds that a majority of Americans think the U.S. should be a world leader in science, but Democrats ...
This recent drop highlights revived worries regarding the initial earnings dilution stemming from its Penumbra ...
Thermo Fisher Scientific is starting 2026's J.P. Morgan Healthcare Conference with a bang, announcing two new deals with an ...
Boston Scientific is spending $14.5 billion in cash and stock to buy Penumbra, another medical-device maker that makes products used in minimally invasive procedures to treat conditions such as blood ...
With the planned purchase, Boston Scientific will gain several thrombectomy devices to remove clots from blood vessels.
Artificial intelligence promises to accelerate scientific discovery and open new frontiers of inquiry. But new research from ...
Boston Scientific is purchasing heart-device company Penumbra for roughly $14.5 billion in cash and stock, marking the ...
Scientific uncertainty persists around 3I/ATLAS after anomalous observations and a CIA FOIA response, despite NASA’s public ...
Boston Scientific said on Thursday it will buy Penumbra in a deal valued at about $14.5 billion to expand its vascular ...
The consequences could be severe. With paylines at most NIH Institutes well below 10 percent, every award not based on merit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback